S Lu1, S Wang, S Geng, S Ma, Z Liang, B Jiao. 1. Department of Neurosurgery, Second Hospital of Hebei Medical University, No. 215, Hepingxi Road, Shijiazhuang, 050000, Hebei, China.
Abstract
OBJECTIVE: MicroRNA-224 (miR-224) has been consistently reported to be dysregulated in various human malignancies and can potentially affect many cancer-related cellular processes, including transcription, cell differentiation, cell death, growth, and cell proliferation. However, its roles in human glioma have not been reported. The aim of this study was to explore the expression pattern, clinical significance, and prognostic value of miR-224 in glioma patients using large cohorts. METHODS: Quantitative real-time polymerase chain reaction analysis was used to characterize the expression patterns of miR-224 in 108 glioma and 20 normal brain tissues. The associations of miR-224 expression with clinicopathological factors and prognosis of glioma patients were also statistically analyzed. RESULTS: miR-224 expression is significantly upregulated in glioma tissues compared with normal brain tissues (P < 0.001). In addition, high expression of miR-224 was significantly associated with advanced pathological grade (P = 0.006) and low Karnofsky performance score (KPS, P = 0.01). Moreover, Kaplan-Meier survival analysis showed that high miR-224 expression group had significantly shorter disease-free survival (DFS) and overall survival (OS) rates than low miR-224 expression group (both P < 0.001). Multivariate analysis with the Cox's proportional hazards model revealed that high expression of miR-224 (P = 0.006 and P = 0.01, respectively) and advanced pathological grade (both P = 0.02) were independent factors for shorter DFS and OS. Furthermore, subgroup analyses showed that miR-224 expression was significantly associated with poor DFS and OS in glioma patients with high pathological grades (for grade III-IV: P < 0.001 and P = 0.005, respectively). CONCLUSIONS: MiR-224 is upregulated and confers a poor prognosis in glioma patients.
OBJECTIVE: MicroRNA-224 (miR-224) has been consistently reported to be dysregulated in various humanmalignancies and can potentially affect many cancer-related cellular processes, including transcription, cell differentiation, cell death, growth, and cell proliferation. However, its roles in humanglioma have not been reported. The aim of this study was to explore the expression pattern, clinical significance, and prognostic value of miR-224 in gliomapatients using large cohorts. METHODS: Quantitative real-time polymerase chain reaction analysis was used to characterize the expression patterns of miR-224 in 108 glioma and 20 normal brain tissues. The associations of miR-224 expression with clinicopathological factors and prognosis of gliomapatients were also statistically analyzed. RESULTS:miR-224 expression is significantly upregulated in glioma tissues compared with normal brain tissues (P < 0.001). In addition, high expression of miR-224 was significantly associated with advanced pathological grade (P = 0.006) and low Karnofsky performance score (KPS, P = 0.01). Moreover, Kaplan-Meier survival analysis showed that high miR-224 expression group had significantly shorter disease-free survival (DFS) and overall survival (OS) rates than low miR-224 expression group (both P < 0.001). Multivariate analysis with the Cox's proportional hazards model revealed that high expression of miR-224 (P = 0.006 and P = 0.01, respectively) and advanced pathological grade (both P = 0.02) were independent factors for shorter DFS and OS. Furthermore, subgroup analyses showed that miR-224 expression was significantly associated with poor DFS and OS in gliomapatients with high pathological grades (for grade III-IV: P < 0.001 and P = 0.005, respectively). CONCLUSIONS:MiR-224 is upregulated and confers a poor prognosis in gliomapatients.
Authors: L Scapoli; A Palmieri; L Lo Muzio; F Pezzetti; C Rubini; A Girardi; F Farinella; M Mazzotta; F Carinci Journal: Int J Immunopathol Pharmacol Date: 2010 Oct-Dec Impact factor: 3.219
Authors: Zsuzsanna Lichner; Salvador Mejia-Guerrero; Monika Ignacak; Adriana Krizova; Tian Tian Bao; Andrew H F Girgis; Yousef M Youssef; George M Yousef Journal: Am J Pathol Date: 2012-02-09 Impact factor: 4.307
Authors: Jakub Godlewski; Michal O Nowicki; Agnieszka Bronisz; Shanté Williams; Akihiro Otsuki; Gerard Nuovo; Abhik Raychaudhury; Herbert B Newton; E Antonio Chiocca; Sean Lawler Journal: Cancer Res Date: 2008-11-15 Impact factor: 12.701
Authors: Pablo Landgraf; Mirabela Rusu; Robert Sheridan; Alain Sewer; Nicola Iovino; Alexei Aravin; Sébastien Pfeffer; Amanda Rice; Alice O Kamphorst; Markus Landthaler; Carolina Lin; Nicholas D Socci; Leandro Hermida; Valerio Fulci; Sabina Chiaretti; Robin Foà; Julia Schliwka; Uta Fuchs; Astrid Novosel; Roman-Ulrich Müller; Bernhard Schermer; Ute Bissels; Jason Inman; Quang Phan; Minchen Chien; David B Weir; Ruchi Choksi; Gabriella De Vita; Daniela Frezzetti; Hans-Ingo Trompeter; Veit Hornung; Grace Teng; Gunther Hartmann; Miklos Palkovits; Roberto Di Lauro; Peter Wernet; Giuseppe Macino; Charles E Rogler; James W Nagle; Jingyue Ju; F Nina Papavasiliou; Thomas Benzing; Peter Lichter; Wayne Tam; Michael J Brownstein; Andreas Bosio; Arndt Borkhardt; James J Russo; Chris Sander; Mihaela Zavolan; Thomas Tuschl Journal: Cell Date: 2007-06-29 Impact factor: 41.582
Authors: Zammam Areeb; Stanley S Stylli; Rachel Koldej; David S Ritchie; Tali Siegal; Andrew P Morokoff; Andrew H Kaye; Rodney B Luwor Journal: J Neurooncol Date: 2015-09-21 Impact factor: 4.130
Authors: Mónika Gyugos; Gábor Lendvai; István Kenessey; Krisztina Schlachter; Judit Halász; Péter Nagy; Miklós Garami; Zsuzsa Jakab; Zsuzsa Schaff; András Kiss Journal: Virchows Arch Date: 2014-02-26 Impact factor: 4.064
Authors: Yu Wang; Jianwei Ren; Yun Gao; Joel Z I Ma; Han Chong Toh; Pierce Chow; Alexander Y F Chung; London L P J Ooi; Caroline G L Lee Journal: PLoS One Date: 2013-07-29 Impact factor: 3.240
Authors: Xiaoyan He; Zhimei Zhang; Ming Li; Shuo Li; Lihua Ren; Hong Zhu; Bin Xiao; Ruihua Shi Journal: BMC Cancer Date: 2015-08-06 Impact factor: 4.430